Want to see HNGE full AI Analyst Report?

Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

195 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HNGE Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Hinge

Health, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HNGE Stock 12 Month Forecast

Average Price Target

$77.00

▲(77.75% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Hinge Health, Inc. Class A in the last 3 months. The average price target is $77.00 with a high forecast of $95.00 and a low forecast of $45.00. The average price target represents a 77.75% change from the last price of $43.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","65":"$65","96":"$96","49.5":"$49.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,49.5,65,80.5,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.07,85.83384615384615,86.5976923076923,87.36153846153846,88.1253846153846,88.88923076923076,89.65307692307692,90.41692307692307,91.18076923076923,91.94461538461539,92.70846153846153,93.4723076923077,94.23615384615384,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.07,84.44923076923077,83.82846153846154,83.2076923076923,82.58692307692307,81.96615384615384,81.34538461538462,80.72461538461538,80.10384615384615,79.48307692307692,78.8623076923077,78.24153846153845,77.62076923076923,{"y":77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.07,81.9876923076923,78.9053846153846,75.82307692307691,72.74076923076923,69.65846153846154,66.57615384615384,63.49384615384615,60.411538461538456,57.32923076923077,54.246923076923075,51.16461538461538,48.082307692307694,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.49,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.07,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$77.00

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Daniels

William Blair

―

Buy

―

Reiterated

06/30/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB) and Hinge Health, Inc. Class A (NYSE: HNGE)

Stan Berenshteyn

Wells Fargo

$80→$90

Buy

107.76%

Upside

Assigned

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Natera (NTRA)

Vikram Kesavabhotla

Robert W. Baird

$55→$65

Hold

50.05%

Upside

Reiterated

06/17/26

Hinge Health price target raised to $65 from $55 at BairdHinge Health price target raised to $65 from $55 at Baird

Richard Close

Canaccord Genuity

$65→$76

Buy

75.44%

Upside

Assigned

06/15/26

Hinge Health price target raised to $76 from $65 at CanaccordHinge Health price target raised to $76 from $65 at Canaccord

Brian Peterson

Raymond James

$70→$80

Buy

84.67%

Upside

Reiterated

06/15/26

Hinge Health price target raised to $80 from $70 at Raymond JamesHinge Health price target raised to $80 from $70 at Raymond James

Scott Schoenhaus

KeyBanc

$75→$90

Buy

107.76%

Upside

Assigned

06/12/26

Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)

Saket Kalia

Barclays

$62→$70

Buy

61.59%

Upside

Assigned

06/11/26

Barclays Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Craig Hettenbach

Morgan Stanley

$72

Buy

66.20%

Upside

Reiterated

06/11/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Hinge Health, Inc. Class A (NYSE: HNGE)

David Grossman

Stifel Nicolaus

$79

Buy

82.36%

Upside

Assigned

06/11/26

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)

Jailendra Singh

Truist Financial

$79→$85

Buy

96.21%

Upside

Reiterated

06/11/26

Truist Financial Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Ryan MacDonald

Needham

$76

Buy

75.44%

Upside

Reiterated

06/11/26

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Hinge Health, Inc. Class A (NYSE: HNGE)

Rishi Jaluria

RBC Capital

$65→$75

Buy

73.13%

Upside

Reiterated

06/10/26

RBC Capital Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Aaron Kimson

Citizens JMP

$65→$80

Buy

84.67%

Upside

Reiterated

05/06/26

Hinge Health price target raised to $80 from $65 at CitizensHinge Health price target raised to $80 from $65 at Citizens

Jessica Tassan

Piper Sandler

$60→$95

Buy

119.30%

Upside

Reiterated

05/06/26

Hinge Health price target raised to $95 from $60 at Piper SandlerHinge Health price target raised to $95 from $60 at Piper Sandler

Elizabeth Anderson CFA

Evercore ISI

$45

Buy

3.88%

Upside

Reiterated

04/30/26

Evercore ISI Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Daniels

William Blair

―

Buy

―

Reiterated

06/30/26

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB) and Hinge Health, Inc. Class A (NYSE: HNGE)

Stan Berenshteyn

Wells Fargo

$80→$90

Buy

107.76%

Upside

Assigned

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Natera (NTRA)

Vikram Kesavabhotla

Robert W. Baird

$55→$65

Hold

50.05%

Upside

Reiterated

06/17/26

Hinge Health price target raised to $65 from $55 at BairdHinge Health price target raised to $65 from $55 at Baird

Richard Close

Canaccord Genuity

$65→$76

Buy

75.44%

Upside

Assigned

06/15/26

Hinge Health price target raised to $76 from $65 at CanaccordHinge Health price target raised to $76 from $65 at Canaccord

Brian Peterson

Raymond James

$70→$80

Buy

84.67%

Upside

Reiterated

06/15/26

Hinge Health price target raised to $80 from $70 at Raymond JamesHinge Health price target raised to $80 from $70 at Raymond James

Scott Schoenhaus

KeyBanc

$75→$90

Buy

107.76%

Upside

Assigned

06/12/26

Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)

Saket Kalia

Barclays

$62→$70

Buy

61.59%

Upside

Assigned

06/11/26

Barclays Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Craig Hettenbach

Morgan Stanley

$72

Buy

66.20%

Upside

Reiterated

06/11/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Hinge Health, Inc. Class A (NYSE: HNGE)

David Grossman

Stifel Nicolaus

$79

Buy

82.36%

Upside

Assigned

06/11/26

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)

Jailendra Singh

Truist Financial

$79→$85

Buy

96.21%

Upside

Reiterated

06/11/26

Truist Financial Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Ryan MacDonald

Needham

$76

Buy

75.44%

Upside

Reiterated

06/11/26

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Hinge Health, Inc. Class A (NYSE: HNGE)

Rishi Jaluria

RBC Capital

$65→$75

Buy

73.13%

Upside

Reiterated

06/10/26

RBC Capital Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Aaron Kimson

Citizens JMP

$65→$80

Buy

84.67%

Upside

Reiterated

05/06/26

Hinge Health price target raised to $80 from $65 at CitizensHinge Health price target raised to $80 from $65 at Citizens

Jessica Tassan

Piper Sandler

$60→$95

Buy

119.30%

Upside

Reiterated

05/06/26

Hinge Health price target raised to $95 from $60 at Piper SandlerHinge Health price target raised to $95 from $60 at Piper Sandler

Elizabeth Anderson CFA

Evercore ISI

$45

Buy

3.88%

Upside

Reiterated

04/30/26

Evercore ISI Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hinge Health, Inc. Class A

3 Months

Saket KaliaBarclays

Success Rate

7/9 ratings generated profit

Average Return

+36.13%

Copying Saket Kalia's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +36.13% per trade.

1 Year

Elizabeth Anderson CFAEvercore ISI

Success Rate

7/7 ratings generated profit

Average Return

+98.19%

Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +98.19% per trade.

2 Years

Elizabeth Anderson CFAEvercore ISI

Success Rate

7/7 ratings generated profit

Average Return

+106.36%

Copying Elizabeth Anderson CFA's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +106.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNGE Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HNGE has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HNGE average Analyst price target in the past 3 months is 77.00.

Each month's total comprises the sum of three months' worth of ratings.

HNGE Financial Forecast

HNGE Earnings Forecast

Next quarter’s earnings estimate for HNGE is $0.61 with a range of $0.47 to $0.70. The previous quarter’s EPS was $0.45. HNGE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Sales Forecast

Next quarter’s sales forecast for HNGE is $201.47M with a range of $200.72M to $203.10M. The previous quarter’s sales results were $182.31M. HNGE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Stock Forecast FAQ

What is HNGE’s average 12-month price target, according to analysts?

Based on analyst ratings, Hinge Health, Inc. Class A’s 12-month average price target is 77.00.

What is HNGE’s upside potential, based on the analysts’ average price target?

Hinge Health, Inc. Class A has 77.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HNGE a Buy, Sell or Hold?

Hinge Health, Inc. Class A has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Hinge Health, Inc. Class A’s price target?

The average price target for Hinge Health, Inc. Class A is 77.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $45.00. The average price target represents 77.75% Increase from the current price of $43.32.

What do analysts say about Hinge Health, Inc. Class A?

Hinge Health, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of HNGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

HNGE Analyst Ratings

HNGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hinge Health, Inc. Class A

HNGE Analyst Recommendation Trends

HNGE Financial Forecast

HNGE Earnings Forecast

HNGE Sales Forecast

HNGE Stock Forecast FAQ

Detailed List of Analyst Forecasts